Compare Enveric Biosciences Inc (ENVB) vs YieldMax MSTR Option Income Strategy ETF (MSTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs YieldMax MSTR Option Income Strategy ETF — how do they compare? Enveric Biosciences Inc trades at $1.48 (market cap $6.80M), while YieldMax MSTR Option Income Strategy ETF trades at $15.68 (market cap $1.06B). The key difference: YieldMax MSTR Option Income Strategy ETF is far larger — about 155.9× Enveric Biosciences Inc's market cap, and Enveric Biosciences Inc is more actively traded (64,867 versus 2,402,888). Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and YieldMax MSTR Option Income Strategy ETF for 30 Days on average.
| ENVB | MSTY | |
|---|---|---|
Market Cap | $6.80M | $1.06B |
Volume | 64,867 | 2,402,888 |
Sector | Health | Income / Options Overlay |
52-Week High | $10.80 | $67.85 |
52-Week Low | $1.27 | $11.55 |
Typical Hold Time | 14 Days | 30 Days |
Enterprise Value | -$1.49M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.48, down 1.0% today, with a bearish technical signal from moving averages but neutral oscillators. The company shows negative profitability with ROE at -235.48% and ROA at -193.53%, though it has beaten EPS expectations for four consecutive quarters. Recent developments include patent allowances for non-hallucinogenic therapeutics and positive preclinical data for EB-003.
While analyst consensus is 75% buy with no sell ratings, fundamental weaknesses in revenue generation and negative cash flow from operations pose significant risks. The stock's appeal hinges on clinical progress and regulatory milestones, making it suitable for risk-tolerant investors betting on biotech innovation amid high operational and financial volatility.
MSTY trades at $15.83, down 5.61% today amid bearish technical signals. The ETF shows mixed sentiment with Seeking Alpha rating it Hold despite a 100.32% annualized distribution rate. Recent articles highlight significant NAV erosion, with $10,000 investments declining to approximately $6,614 over six months according to 24/7 Wall Street analysis from July 2026.
The fund's high distribution strategy comes with substantial principal erosion risk. While weekly dividends provide income, the structural design returns investor capital as distributions. Analyst consensus remains cautious due to the fund's dependence on MSTR volatility and ongoing NAV decline, making this suitable only for sophisticated investors understanding the income-principal tradeoff.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About YieldMax MSTR Option Income Strategy ETF
MSTY is an actively managed ETF that pursues a synthetic covered call strategy on MicroStrategy Incorporated (MSTR) stock. The fund primarily sells call options on MSTR and invests in U.S. Treasury securities and other high-quality collateral. Its goal is to generate monthly income from the option premiums. This strategy provides exposure to the volatile, Bitcoin-correlated growth potential of MSTR while seeking to deliver a high yield, though it caps the potential capital appreciation of the stock.
Read more on MSTY →
